• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·GENB
Held by 1 Guru
Share

Generate Biomedicines, Inc. Stocks

$ 15.64Last Updated 14.08.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 2.00B

$ 15.64
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Cathie Wood

Portfolio Weight (%)

0.1%

Change

+0.09%

Fund

ARK Investment Management LLC

Manager
Fund
Portfolio Weight (%)
Change
Cathie WoodARK Investment Management LLC0.1%+0.09%

Latest news

09.07.2026 12:10

Anthropic will focus on drug development. How can one profit from AI in the pharmaceutical sector?

01.03.2026 22:00

$110 billion OpenAI, SpaceX and crypto-payments operator RedotPay: What's important about the IPO by March 1

27.02.2026 15:00

IPO Generate Biomedicines: shares of AI drug development platform become available

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of GENB is 26.4 and suggests 68.5% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.08.2026 12:44

Tech Giants Have Hidden $3 Trillion in AI Liabilities Off Their Balance Sheets — WSJ

17.08.2026 11:20

Andrey Doronichev's biotech startup, Bioptic, is considering an IPO

17.08.2026 11:00

"New Leaders Will Rise from the Ashes": An Interview with Entrepreneur Andrei Doronichev

17.08.2026 10:27

Walmart's Earnings Report, the Fed Minutes, and Business Activity: What Investors Can Expect This Week

16.08.2026 21:00

Anthropic Is Aiming for a Record; Whoop Is Expanding Its Workforce: Key Takeaways on the IPO by August 16

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026